Tempest Therapeutics, Inc. — Director's Dealing 2015

May 28, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2015-05-26

Reporting Person: Dipp Michelle (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-05-26	Common Stock	P	300	$31.02	Acquired	987713	Direct

Footnotes

F1: The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.

F2: Represents 960,673 shares of common stock and 27,040 RSUs.